Our Company

We are a biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ophthalmic diseases

OUR MISSION

Kodiak aims to prevent and treat the leading causes of blindness in the developed world

TRAILBLAZING SCIENCE

OUR CREATIVE AND THOUGHTFUL FOUNDATION

“GO-TO” MEDICINES

OUR CHALLENGE TO THE STATUS QUO

SINGULAR FOCUS IN OPHTHALMOLOGY

OUR 24/7/365

THE TEAM

Together, our team has acquired decades of experience needed to solve some of the most challenging issues in ophthalmology

Victor Perlroth, M.D.
Chairman and Chief Executive Officer

John Borgeson
Chief Financial Officer

Dolly S. Chang, M.D., M.P.H., Ph.D
Chief Scientific Officer

Almas Qudrat, M.Sc.
Chief Quality Officer

Pablo Velazquez-Martin, M.D.
Chief Medical Officer

Laurent Ducry, Ph.D.
Senior Vice President, Biologics Development and Manufacturing

Hong Liang, Ph.D.
Senior Vice President, Development

Stephen Raillard, Ph.D.
Senior Vice President, Chemical Development and Manufacturing

Gorton Chiu
Vice President, Finance

BOARD OF DIRECTORS

Victor Perlroth, M.D.
Chairman and Chief Executive Officer

Robert A. Profusek, J.D.
Partner and Global Chair M&A, Jones Day

Felix J. Baker, Ph.D.
Managing Member, Baker Brothers Investments

Bassil I. Dahiyat, Ph.D.
President and Chief Executive Officer, Xencor Inc.

Richard S. Levy, M.D.
Formerly Chief Drug Development Officer and Executive Vice President, Incyte Corporation

Taiyin Yang, Ph.D.
Formerly Executive Vice President, Pharmaceutical Development & Manufacturing, Gilead Sciences Inc.

Charles A. Bancroft
Formerly Chief Financial Officer, Bristol-Myers Squibb

OUR MILESTONES

2018

July 2018

Kodiak initiates its first Phase 1a clinical study of KSI-301, an antibody biopolymer conjugate, in patients with diabetic macular edema (DME)

2018

July 2018

Kodiak initiates its first Phase 1a clinical study of KSI-301, an antibody biopolymer conjugate, in patients with diabetic macular edema (DME)

Oct 2018

Kodiak goes public, raising $90 million and is listed on NASDAQ as KOD

2018

Dec 2018

Kodiak presents Phase 1a clinical study data demonstrating safety and durability of response following a single dose of KSI-301 in patients with DME

Dec 2018

Based on promising Phase 1a data in DME, we expand KSI-301 into a Phase 1b study in patients with wet age-related macular degeneration (wAMD), DME and retinal vein occlusion (RVO)

2018

2019

Jul 2019

Kodiak presents positive interim data from ongoing Phase 1b clinical study of KSI-301 for the treatment of wet AMD, DME and RVO

Oct 2019

Kodiak treats first patients in DAZZLE, its initial Phase 2b/3 study of KSI-301 in patients with wet AMD

2019

Dec 2019

Kodiak announces sale of future royalties on KSI-301 for $225 million

Oct 2020

Kodiak treats first patients in three additional Phase 3 pivotal studies of KSI-301—two studies in DME (GLEAM and GLIMMER) and one study in macular edema due to RVO (BEACON)

2020

2021

Feb 2021

Kodiak presents promising 1-year durability, efficacy and safety data from its Phase 1b study of KSI-301 in patients with wet AMD, DME and RVO

Jun 2021

First patients treated in DAYLIGHT Phase 3 study of KSI-301 in patients with wet AMD

2021

Sep 2021

First patients treated in GLOW Phase 3 study of KSI-301 in patients with non-proliferative Diabetic Retinopathy (DR) without DME

Feb 2022

Topline results from DAZZLE Phase 2b/3 study in patients with wet AMD announced

2022

May 2022

Kodiak and Lonza announce grand opening of Kodiak Sciences’ purpose built bioconjugation facility to support potential commercial manufacture of KSI-301

Aug 2022

Kodiak Sciences reports positive topline results from BEACON Phase 3 Study of tarcocimab tedromer (KSI-301) in patients with RVO

2022

2023

Apr 2023

Kodiak Sciences expands development pipeline with treatment of first patient in Phase 1 clinical study of KSI-501, an investigational bispecific Antibody Biopolymer Conjugate for retinal diseases

Sept 2023

New one-year results of tarcocimab in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in RVO

2023

Oct 2023

Positive primary results announced of tarcocimab in the Phase 3 DAYLIGHT study in wet AMD. Primary results and new analyses of the Phase 3 GLEAM and GLIMMER studies in DME also reported.

Nov 2023

Following strong positive results of tarcocimab in the Phase 3 GLOW study in DR, Kodiak expects to conduct one confirmatory pivotal study with a commercial formulation to support a single BLA submission across DR, RVO and wet AMD

2023

2024

Jan 2024

Kodiak presents first time results of KSI-501 Phase 1 study in patients with DME. These early results support further clinical development of the KSI-501 program

May 2024

Kodiak announces treatment of first patients in Phase 3 GLOW2 study of tarcocimab tedromer in diabetic retinopathy

2024

Aug 2024

Kodiak announces that the Phase 3 DAYBREAK study of tarcocimab and KSI-501, featuring an innovative study design that includes parallel investigational arms of tarcocimab and KSI-501 against aflibercept in wet AMD, is actively enrolling patients. The Phase 1b APEX study of KSI-101 in patients with macular edema secondary to inflammation has also been activated and is recruiting patients.

Sep 2024

Kodiak hosts an Investor R&D Day in New York and presents important updates across the clinical program including new clinical data supporting why tarcocimab and KSI-501, built on Kodiak’s ABCD platform, are built to last and how their enhanced formulations are designed for both strong immediacy and sustained durability. We also do a deep dive into the study designs of our enrolling Phase 3 studies (DAYBREAK and GLOW2) and Phase 1b APEX study.

2024

2025

Jan 2025

Kodiak presents Phase 1b clinical study data of KSI-101 from the APEX study. Strong treatment response demonstrated at all KSI-101 dose levels, driving program acceleration.

Feb 2025

Kodiak advances its ABCD platform technology to additional high-prevalence retinal diseases. Kodiak’s novel ABCD “duet” therapy for the treatment of glaucoma presented at the Glaucoma 360 New Horizons Forum.

2025

OUR COMPANY

OUR MISSION

TRAILBLAZING SCIENCE

“GO-TO” MEDICINES

SINGULAR FOCUS IN OPHTHALMOLOGY

THE TEAM

BOARD OF DIRECTORS

OUR MILESTONES

FORWARD LOOKING STATEMENTS